J&J Stock Ahead of Q3 Earnings: Should You Buy, Sell or Hold?

JNJ heads into Q3 earnings with strong drug sales and new launches, but Stelara biosimilar competition and MedTech challenges could weigh on growth.

09.10.2026

4 Dividend Stocks Boomers Can Safely Buy Now and Hold Forever

Four Dividend Kings with streaks stretching back decades sit inside millions of retirement portfolios, but one of them is spending every dollar of free cash flow just to keep its streak alive.

09.10.2026

New Johnson & Johnson ICOTYDE® (icotrokinra) long-term data demonstrate robust 2-year results in the treatment of adults and adolescents with plaque psoriasis

Phase 3 data presented at Fall Clinical Dermatology show high, sustained response rates in adults and adolescents, with nearly three-quarters achieving clear or almost clear skin at two years and a continued favorable safety profile SPRING HOUSE, Pa., Oct. 9, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new two-year results from the Phase 3 ICONIC-LEADa study evaluating ICOTYDE® (icotrokinra), the first and only targeted oral peptide that precisely blocks the IL-23 receptor1, in adults and pediatric patients 12 years of age and older (adolescents) with moderate-to-severe plaque psoriasis.

08.10.2026

HALO Wins Court Order Blocking Merck's Keytruda SC in Europe

Halozyme wins a Dutch court order blocking Merck's Keytruda SC in eight European markets, strengthening its position in the patent dispute.

08.10.2026

Will Johnson & Johnson (JNJ) Beat Estimates Again in Its Next Earnings Report?

Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

08.10.2026

Big Yields Are Easy to Find. These 4 Dividend Stocks Have Something Better

A fat yield can vanish overnight, but four dividend stocks on this list show you exactly where the cash comes from before you buy a single share.

08.10.2026

Johnson & Johnson (JNJ) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates

Besides Wall Street's top-and-bottom-line estimates for Johnson & Johnson (JNJ), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2026.

Videolar

14.08.2026

Positive

Expert explains why healthcare is a top-performing sector

02.08.2026

Positive

Inside J&J's Lab to Create a Simpler Robotic Surgery Device

Reytinglar oshishi / pasayishi

Ticker	Tashkilot	Reyting o‘zgarishi	Maqsadli narx	Sana
JNJ	UBS	Buy	undefined >> $320	September 2nd 2026

Press-relizlar

09.10.2026

New Johnson & Johnson ICOTYDE® (icotrokinra) long-term data demonstrate robust 2-year results in the treatment of adults and adolescents with plaque psoriasis

Johnson & Johnson (JNJ)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Biz bilan bog'lanish

Bizni kuzating

Johnson & Johnson (JNJ)

J&J Stock Ahead of Q3 Earnings: Should You Buy, Sell or Hold?

4 Dividend Stocks Boomers Can Safely Buy Now and Hold Forever

New Johnson & Johnson ICOTYDE® (icotrokinra) long-term data demonstrate robust 2-year results in the treatment of adults and adolescents with plaque psoriasis

HALO Wins Court Order Blocking Merck's Keytruda SC in Europe

Will Johnson & Johnson (JNJ) Beat Estimates Again in Its Next Earnings Report?

Big Yields Are Easy to Find. These 4 Dividend Stocks Have Something Better